Table 2.
Clinical trials with the use of stem cells from human umbilical cords.
| Treated Condition | Number of Study Participants | Type of Study | Source of Stem Cells/Number of Donors | Mean Dose of Stem Cells in One Injection | Delivery Method | Author | Publication Date | Journal |
|---|---|---|---|---|---|---|---|---|
| Acute myocardial infarction | 116 | Randomized double-blind controlled trial | Wharton’s jelly/pooled from 21 donors | 6 × 106 | Intracoronary infusion | Gao et al. [96] | 2015 | BMC Medicine |
| Amyotrophic lateral sclerosis | 43 | Not specified | Wharton’s jelly/pooled from three donors | 0.42 × 106/kg of body weight | Intrathecal injection | Barczewska et al. [97] | 2019 | Neural Regeneration Research |
| HIV-1-infected immune nonresponders | 13 | Prospective open-labeled controlled trial | Wharton’s jelly/not specified | 0.5 × 106/kg of body weight | Intravenous infusion | Zhang et al. [98] | 2013 | AIDS |
| Active and refractory systemic lupus erythematosus | 40 | Multicenter trial | Umbilical cord (not specified)/not specified | 1 × 106/kg of body weight | Intravenous infusion | Wang et al. [99,102] |
2014; 2014 |
Arthritis Research and Therapy;
Arthritis and Rheumatology |
| Neuromyelitis optica | 5 | Not specified | Umbilical cord (not specified)/not specified | 4 × 107 or 2 × 107 | Intravenous and intrathecal infusion | Lu et al. [100] | 2012 | Current Neurovascular Research |
| Rheumatoid arthritis | 172 | Single center trial | Umbilical cord (not specified)/not specified | 4 × 107 | Intravenous infusion | Wang et al. [101] | 2013 | Stem Cells and Development |
| Type 1 diabetes mellitus | 29 | Randomized double-blind controlled trial | Wharton’s jelly/one donor | 2.6 ± 1.2 × 107 | Intravenous infusion | Hu et al. [103] | 2013 | Endocrine Journal |
| Type 2 diabetes mellitus | 22 | Single center prospective trial | Wharton’s jelly/not specified | 1 × 106/kg of body weight | Intravenous infusion and intra-pancreatic endovascular injection | Liu et al. [104] | 2014 | Stem Cell Research and Therapy |
| Autism | 37 | Non-randomized open-label, single center trial | Wharton’s jelly/not specified | 1 × 106/kg of body weight | Intravenous and intrathecal infusion | Lv et al. [105] | 2013 | Journal of Translational Medicine |
| High risk leukemia | 20 | Randomized trial | Wharton’s jelly/not specified | 1 × 106/kg of body weight | Intravenous infusion | Wu et al. [106] | 2013 | Cell Transplantation |